Skip to content

Advertisement

Arthritis Research & Therapy

  • Research article
  • Open Access

Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout

  • Cushla McKinney1,
  • Lisa K. Stamp2,
  • Nicola Dalbeth3,
  • Ruth K. Topless1,
  • Richard O. Day4, 5,
  • Diluk RW Kannangara4, 5,
  • Kenneth M. Williams4, 5,
  • Matthijs Janssen6,
  • Timothy L. Jansen7, 8,
  • Leo A. Joosten9,
  • Timothy R. Radstake10, 11,
  • Philip L. Riches12,
  • Anne-Kathrin Tausche13,
  • Frederic Lioté14, 15,
  • Alexander So16 and
  • Tony R. Merriman1Email author
Arthritis Research & Therapy201517:288

https://doi.org/10.1186/s13075-015-0802-3

©  McKinney et al. 2015

Received: 12 July 2015

Accepted: 26 September 2015

Published: 13 October 2015

Abstract

Introduction

The acute gout flare results from a localised self-limiting innate immune response to monosodium urate (MSU) crystals deposited in joints in hyperuricaemic individuals. Activation of the caspase recruitment domain-containing protein 8 (CARD8) NOD-like receptor pyrin-containing 3 (NLRP3) inflammasome by MSU crystals and production of mature interleukin-1β (IL-1β) is central to acute gouty arthritis. However very little is known about genetic control of the innate immune response involved in acute gouty arthritis. Therefore our aim was to test functional single nucleotide polymorphism (SNP) variants in the toll-like receptor (TLR)-inflammasome-IL-1β axis for association with gout.

Methods

1,494 gout cases of European and 863 gout cases of New Zealand (NZ) Polynesian (Māori and Pacific Island) ancestry were included. Gout was diagnosed by the 1977 ARA gout classification criteria. There were 1,030 Polynesian controls and 10,942 European controls including from the publicly-available Atherosclerosis Risk in Communities (ARIC) and Framingham Heart (FHS) studies. The ten SNPs were either genotyped by Sequenom MassArray or by Affymetrix SNP array or imputed in the ARIC and FHS datasets. Allelic association was done by logistic regression adjusting by age and sex with European and Polynesian data combined by meta-analysis. Sample sets were pooled for multiplicative interaction analysis, which was also adjusted by sample set.

Results

Eleven SNPs were tested in the TLR2, CD14, IL1B, CARD8, NLRP3, MYD88, P2RX7, DAPK1 and TNXIP genes. Nominally significant (P < 0.05) associations with gout were detected at CARD8 rs2043211 (OR = 1.12, P = 0.007), IL1B rs1143623 (OR = 1.10, P = 0.020) and CD14 rs2569190 (OR = 1.08; P = 0.036). There was significant multiplicative interaction between CARD8 and IL1B (P = 0.005), with the IL1B risk genotype amplifying the risk effect of CARD8.

Conclusion

There is evidence for association of gout with functional variants in CARD8, IL1B and CD14. The gout-associated allele of IL1B increases expression of IL-1β – the multiplicative interaction with CARD8 would be consistent with a synergy of greater inflammasome activity (resulting from reduced CARD8) combined with higher levels of pre-IL-1β expression leading to increased production of mature IL-1β in gout.

Keywords

GoutMultiplicative InteractionSerum Urate LevelAcute Gouty ArthritisIL1B Rs1143623

Introduction

The immediate cause of gout is the deposition of monosodium urate (MSU) crystals in and around body tissues, particularly joints [1]. Initially, these deposits trigger a localised and self-limiting inflammatory response (acute gouty arthritis), which becomes increasingly frequent and severe, involving multiple joints and associated with fever. Monosodium urate crystals form under hyperuricaemic conditions when serum urate levels exceed the physiological saturation level (approximately 6.8 mg/dL; approximately 0.41 mM). The most significant biological cause of hyperuricaemia is relatively low renal clearance of uric acid [2, 3]. This is consistent with findings from genome-wide association studies in which 28 loci associated with serum urate levels have been identified, some of which are in genes involved in renal uric acid handling [4, 5]. Predictably most, but not all, of the 28 loci have been associated with gout [4, 6].

Although hyperuricaemia is a prerequisite for MSU formation, only a relatively small proportion of individuals with hyperuricaemia develop gout [7]. This indicates that beside genetic variants associated with urate metabolism and excretion, other factors contribute to the pathogenesis of gout. MSU crystals play an important role in activation of the innate immune system [8] and the recognition of gout as an auto-inflammatory disorder is consistent with the results of functional studies [9, 10]. Variations within genes of the innate immune system may therefore determine whether MSU crystals trigger an inflammatory reaction in susceptible individuals, leading to acute gout; while in others, no inflammation is elicited. Genetic variants that influence the activation and function of the NOD-like Receptor Pyrin containing 3 (NLRP3) inflammasome are candidate genes in this context [11]. The multi-protein inflammasome complex, comprising the NLRP3 polypeptide, ASC or PYCARD (apoptosis-associated speck-like protein containing a CARD) and caspase-1 [12] forms when monocytes and macrophages encounter damaged and pathogen-associated molecular pattern proteins (DAMPs and PAMP; e.g., bacterial lipopolysaccharide or MSU crystals) and leads to activation of caspase-1. Active caspase-1 processes the pro-interleukin (IL)-1β to the mature pro-inflammatory cytokine IL-1β that is then secreted [12].

CARD8 (also known as TUCAN or Cardinal) is a protein with a caspase-domain that interacts with caspase-1 and inhibits its activation [13] and also with a FIIND domain that binds to NLRP3 preventing its recruitment into the active inflammasome complex [14, 15]. Genetic associations between variants of CARD8 and autoimmune diseases have been previously reported (reviewed in [16]). The T allele of CARD8 rs2043211 (C10X) has been associated with increased risk of gout in Chinese [17], and rs2149356 in toll-like receptor 4 (TLR4), a receptor functionally implicated in MSU-stimulated inflammation [18], has also been associated with serum IL-1β levels and the risk of gout in Han Chinese [19]. However, using a haplotype tagging approach, there is no evidence of association between NLRP3 and gout in Chinese [20].1

Our aim was to extend the findings from the Han Chinese population [17] and to test genetic variants influencing inflammasome function for association with gout in other population groups. Eleven functional variants were tested in eight genes involved in the MSU crystal-mediated activation of the NLRP3-inflammasome and production of mature IL-1β for association with gout in people of European and New Zealand (NZ) Polynesian (Māori and Pacific Island) ancestry. The prevalence of gout in the NZ Polynesian population is 6–8 % (compared to 3 % in NZ European), exhibiting the highest prevalence worldwide [21, 22].

Methods

Participants, ethics and consent

The study was carried out on sample sets comprising: a NZ Polynesian sample set consisting of 1,893 individuals of Samoan, Tongan, Niuean, Cook Island Māori and NZ Māori descent (Table 1; 863 cases and 1,030 controls); and a sample set consisting of 1,684 cases of European ancestry (957 recruited from NZ and Australia and 727 recruited from Europe (‘Eurogout’) [23]) and 882 NZ European controls. All people with gout met the 1977 preliminary American Rheumatism Association classification criteria for gout [24]. New Zealand gout cases were recruited from the Auckland and Christchurch regions of NZ, Australian gout cases from an outpatient clinic in Adelaide, Australian private practice rheumatologists and from a previously reported pharmacogenetic study [25]. European gout cases were recruited from outpatient clinics in Edinburgh, Lausanne, Dresden, Arnhem and Nijmegen. The NZ controls did not have any self-reported history of arthritis, were >17 years of age and were convenience sampled from the Auckland, Christchurch and Otago regions of NZ. The New Zealand Multi-Region Ethics Committee (MEC/105/10/130) and these institutional committees in Europe and Australia granted ethical approval: Research Ethics Committee, University of New South Wales; Ethikkommission, Technische Universität Dresden (EK 8012012); South East Scotland Research Ethics Committee (04/S1102/41); Commission Cantonale (VD) D'éthique de la Recherche sur l'être Humain, Université de Lausanne; Commissie Mensgebonden Onderzoek regio Arnhem Nijmegen. All subjects gave written and informed consent.
Table 1

Age, sex and serum urate details of studied sample sets

Sample set

 

Male,

Female,

  

number (%)

Average agea (range)

Average serum urate mmol/Lb (range)

number (%)

Average agea (range)

Average serum urate mmol/Lb (range)

Eastern Polynesian

Gout

365 (76.5)

37.8 (8–78)

0.47 (0.11–0.98)

112 (23.5)

51.0 (10–81)

0.45 (0.10–0.74)

Control

268 (38.0)

42.5 (17–85)

0.41 (0.13–0.67)

437 (62.0)

46.5 (17–88)

0.34 (0.15–0.58)

Western Polynesian

Gout

341 (91.9)

35.1 (11–75)

0.49 (0.17–0.84)

30 (8.1)

43.8 (14–80)

0.49 (0.22–0.72)

Control

175 (56.8)

38.3 (18–72)

0.42 (0.19–0.73)

133 (43.2)

41.2 (17–58)

0.35 (0.14–0.67)

Australasian

Gout

794 (82.7)

45.9 (5–92)

0.42 (0.11–0.80)

163 (17.3)

62.6 (20–90)

0.39 (0.13–0.74)

Control

465 (53.0)

52.3 (18–87)

0.38 ( 0.18–0.77)

412 (47.0)

44.9 (17–95)

0.27 (0.13–0.59)

Eurogout

Gout

628 (86.4)

44.9 (16–83)

0.42 (0.09–0.92)

99 (13.6)

57.5 (30–92)

0.47 (0.13–0.88)

FHS

Control

1681 (53.7)

40.8 (19–69)

0.38 (0.13–0.67)

1450 (46.3)

43.9 (23–58)

0.26 (0.07–0.54)

ARIC

Control

3172 (45.4)

54.3 (44–66)

0.39 (0.08–0.71)

3817 (54.6)

55.6 (45–65)

0.31 (0.03–0.66)

All European

Gout

1422 (84.5)

45.5 (5–92)

0.42 0.09–0.92)

262 (15.5)

60.9 (20–92)

0.42 (0.13–0.88)

Control

5318 (61.9)

50.0 (18–87)

0.38 (0.08–0.77)

5679 (38.1)

49.9 (17–95)

0.29 (0.03–0.66)

aAge at diagnosis for gout cases, at recruitment for controls. bSerum urate levels at recruitment. Data presented for individuals for whom sex information was available

Control subjects of European ancestry, who had been genotyped genome-wide, were also included from the Atherosclerosis Risk in Communities (ARIC) study (n = 6,989) and the Framingham Heart Study (FHS; n = 3,131). Participants with self-reported gout were excluded. The sample sets were also screened to remove all but one representative of any closely related family grouping (full/half siblings and parent/child duos and trios). The ARIC study and FHS analyses (project #834) were approved by the relevant Database of Genotype and Phenotype (dbGaP; [26]) Data Access Committees.

Genotyping and imputation

A Sequenom MassARRAY System was used for genotyping the 4,269 individuals without genome-wide genoytpe data available as previously described [27]. Publicly available genome-wide genotype data from ARIC and FHS were imputed as required to obtain genotypes from the eleven selected SNPs. Imputations were carried out by IMPUTE V2.2 software based on the combined 1000 Genomes V3 population reference set. Individuals and SNPs with a call rate of <0.98 were excluded from analysis, as were monomorphic markers and those with a minor allele frequency of <0.01, and a post-imputation quality threshold of 0.30 was used. Imputations were successful for all eleven SNPs and all imputed SNPs were in Hardy-Weinberg equilibrium (P >0.005) with the exception of NLRP3 rs7512998 in ARIC (P HWE = 1.3 × 10-27) - these data were excluded from analysis. Where necessary, imputed data were strand-adjusted to match the strand interrogated by the Sequenom data prior to analysis.

Association testing

Allelic association analysis was carried out using R software and adjusting for age and sex. For Polynesian samples, a genetically estimated proportion of Polynesian ancestry, calculated as previously described [27], was included as an additional covariate. All odds ratios are reported relative to the minor allele present in the genotyped NZ European control sample set. Meta-analyses were carried out using METAL [28] with weighting based on standard error and log (odds ratio (OR)) as the effect variable. Significant association was declared if P was <0.05 in the European and Polynesian meta-analysis. No correction for multiple testing was applied because there is prior functional evidence for each variant tested.

Power curves are shown in Additional file 1. The Polynesian sample set was adequately powered to detect common effects (minor allele frequency (MAF) >0.1) of OR ≥1.4, whereas the European sample set was adequately powered to detect common effects of MAF >0.2 at OR >1.2 and stronger effects (OR >1.4) at lower MAF (>0.05).

Interaction analysis

As reviewed by Cordell [29] there are a number of ways to test for interaction or a departure from additivity. We used Stata 13.1 software to carry out logistic regression analysis comparing the disease risk for heterozygosity and minor allele homozygosity for each locus individually and in combination. Previously we reported a large allele frequency difference at ABCG2 rs2231142 and heterogeneity in association with gout between Eastern (EP) and Western (WP) Polynesian sample sets [30]. Similarly, there are differences in allele and genotype frequencies between the two groups (Additional file 2), and heterogeneity will be magnified in combined genotypes. Therefore, in the interaction analysis adjustment was made separately for EP and WP, along with European data. An interaction term was included and a P value <0.017 (Bonferroni-adjusted for number of interaction analyses performed) was considered to indicate significant multiplicative interaction between genetic variants.

Results

Eleven functional genetic variants in NLRP3, CARD8, IL1B, DAPK1, TXNIP, TLR2, P2XR7, MYD88 and CD14 were selected from the literature (Table 2) and genotyped; genotype distributions are presented in Additional file 2. There was nominal allelic association (P <0.05) for three variants in the combined European and Polynesian analysis (Table 3) - IL1B, CARD8 and CD14 (OR = 1.10, 1.12 and 1.08, respectively). CARD8 rs2043211 was also associated with gout in Europeans (OR = 1.11).
Table 2

Eleven genetic variants in NLRP3, CARD8, DAPK1, TXNIP, TLR2, P2XR7, MYD88 and CD14 were selected from the literature

SNP (gene)

Functional information

Association with auto-inflammatory phenotype

rs10754558 (NLRP3) NLRP3 is a component of the NALP3 inflammasome.

Variant influences transcription (G > C) [46]

None

rs35829419 (NLRP3)

Gain-of-function, with CARD8pC10X identified in arthritic patient with abnormally high IL-1 [47, 48]

Minor allele protective against celiac disease in a small study [49]

rs7512998 (NLRP3)

None

Refer endnote 1 [20]

rs2043211 (CARD8). CARD8 is a negative regulator of IL-1β secretion

C10X encodes a truncated protein that does not abrogate NFkB transcription [50]. Can be evaded by alternative splicing [51]. Identified as F102I in dbSNP

Interacts with NLRP3 rs35892419 in risk of Crohn’s disease [31]. Associated with disease severity in RA [50]

rs1143623 (IL1B). IL-1β is a pro-inflammatory cytokine produced by activated NALP3 inflammasome

Promoter variant influences IL6 levels after fatty-acid rich meals [38] and IL-1β levels in small Crohn’s disease study [52]

G allele associated with protection from RA [53]

rs4696480 (TLR2). Toll-like receptor involved in NALP3 inflammasome activation

Within binding site for the THP-1-derived nuclear protein, influences reporter expression [54]

None

rs2569190 (CD14). CD14 is an adaptor molecule used by TLR2

Rs2569190 T allele alters transcriptional activity [42, 43]

On meta-analysis is associated with Crohn’s disease [55] and asthma [56]

rs6853 (MYD88). MYD88 is a transducer in the TLR signalling pathway

A allele creates potential miR-562b binding site [57]

None

rs17525809 (P2RX7). Purine receptor involved in a pathway of NALP3 activation via amyloid A

Missense variant (Val > Ala), T allele reduces activity [58]

None

rs4878104 (DAPK1). DAPK1 (death associated kinase) is involved in NALP3 assembly.

Exhibits allelic specific differences in expression [59]

None

rs7212 (TXNIP). TXNIP is thioredoxin-interacting protein required for full inflammasome activation

Increased mRNA expression in smooth muscle cells with G allele [60]

None

NALP3 NACHT, LRR and PYD domains containing protein 3, CARD8 caspase recruitment domain-containing protein 8, RA rheumatoid arthritis, TLR toll-like receptor, NLRP3 NOD-like Receptor Pyrin containing 3

Table 3

Analysis of associations between the minor alleles of the eleven variants and gout

 

European

Polynesian

Meta-analysis

Gene, SNP, minor allele

MAF case

MAF control

OR (95 % CI)

P

MAF case

MAF control

OR (95 % CI)

P

OR (StdErr)

P

NLRP3, rs10754558, G

0.408

0.418

0.95 (0.87–1.04)

0.25

0.459

0.434

1.07 (0.91–1.24)

0.42

0.96 (0.036)

0.44

NLRP3, rs35829419, A

0.046

0.047

0.88 (0.71–1.07)

0.20

0.004

0.012

0.58 (0.20–1.53)

0.29

0.87 (0.098)

0.15

NLRP3, rs7512998, C

0.170

0.160

1.09 (0.94–1.27)

0.25

0.033

0.045

1.03 (0.67–1.60)

0.88

1.08 (0.075)

0.29

CARD8, rs2043211, T

0.338

0.321

1.11 (1.01–1.22)

0.023

0.499

0.439

1.15 (0.98–1.35)

0.078

1.12 (0.042)

0.007

IL1B, rs1143623, G

0.278

0.266

1.09 (0.99–1.20)

0.066

0.532

0.481

1.14 (0.98–1.33)

0.098

1.10 (0.042)

0.020

TLR2, rs4696480, T

0.495

0.499

1.02 (0.93–1.11)

0.68

0.482

0.490

0.98 (0.84–1.15)

0.84

1.01 (0.036)

0.74

CD14, rs2569190, A

0.496

0.475

1.08 (0.99–1.18)

0.070

0.576

0.542

1.07 (0.92–1.26)

0.37

1.08 (0.036)

0.036

MYD88, rs6853, G

0.112

0.120

0.88 (0.77–1.00)

0.059

0.026

0.028

1.18 (0.71–1.98)

0.52

0.90 (0.068)

0.11

P2RX7, rs17525809, C

0.071

0.068

1.09 (0.92–1.29)

0.30

0.056

0.068

0.78 (0.56–1.08)

0.13

1.01 (0.080)

0.87

DAPK1, rs4878104, T

0.358

0.353

1.02 (0.93–1.11)

0.72

0.701

0.622

1.13 (0.96–1.34)

0.14

1.05 (0.044)

0.32

TNXIP, rs7212, G

0.050

0.041

1.27 (1.04–1.55)

0.020

0.191

0.175

1.00 (0.82–1.22)

0.98

1.13 (0.071)

0.091

SNP single nucleotide polymorphism, MAF minor allele frequency, OR odds ratio, StdErr standard error

Because of reported interactions between NLRP3 and CARD8 in other auto-inflammatory conditions [30, 31], and the biological interaction between the inflammasome and IL-1β we tested for pairwise multiplicative interaction between NLRP3/CARD8, NLRP3/IL1B and CARD8/IL1B (Table 4), using only rs10754558 of NLRP3 owing to the low MAF of rs35829419 in both Europeans and Polynesians and the low MAF of rs7512998 in Polynesians. There was evidence for interaction between CARD8 and IL1B (P = 0.005, P c = 0.015), driven by amplification of the risk conferred by the CARD8 rs2043211 T allele in the presence of the rs1143623 IL1B minor allele homozygous (GG) genotype. Nominally significant interaction between NLRP3/IL1B (P Nominal  = 0.048) was also observed, although this was not significant after adjustment for multiple testing (P c = 0.144).
Table 4

Interaction analysis: genotype combinations of CARD8 rs2043211 and NLRP3 rs10754558, CARD8 rs2043211 and IL1B rs1143623, and NLRP3 rs10754558 and IL1B rs1143623

 

Number (%)

  

Combination

Cases

Controls

OR (95 % CI)

P a

rs10754558- rs2043211 (NLRP3-CARD8)

    

CC/AA

318 (0.127)

1,862 (0.155)

1.00

 

CC/AT

376 (0.150)

1,722 (0.144)

1.17 (0.96–1.42)

0.11

CC/TT

133 (0.053)

476 (0.040)

1.55 (1.18–2.04)

0.001

CG/AA

450 (0.180)

2,606 (0.217)

0.94 (0.78–1.13)

0.53

CG/AT

583 (0.233)

2,565 (0.214)

1.16 (0.97–1.38)

0.11

CG/TT

186 (0.074)

635 (0.053)

1.45 (1.11–1.81)

0.006

GG/AA

172 (0.069)

964 (0.080)

0.95 (0.75–1.20)

0.65

GG/AT

206 (0.082)

905 (0.076)

1.22 (0.97–1.54)

0.085

GG/TT

80 (0.032)

258 (0.022)

1.71 (1.23–2.39)

0.002

rs1143623-rs2043211 (IL1B-CARD8)

    

CC/AA

430 (0.174)

2,821 (0.236)

1.00

 

CC/AT

488 (0.197)

2,740 (0.229)

1.13 (0.96–1.32)

0.16

CC/TT

136 (0.055)

644 (0.054)

1.26 (0.99–1.62)

0.066

CG/AA

390 (0.157)

2,182 (0.182)

1.10 (0.92–1.31)

0.28

CG/AT

495 (0.200)

1,979 (0.165)

1.48 (1.25–1.75)

4.3 × 10−6

CG/TT

162 (0.065)

575 (0.048)

1.74 (1.36–2.22)

8.7 × 10−6

GG/AA

112 (0.045)

425 (0.036)

1.33 (1.00–1.77)

0.049

GG/AT

166 (0.067)

465 (0.039)

1.61 (1.25–2.07)

2.0 × 10−4

GG/TT

100 (0.040)

147 (0.012)

3.77 (2.65–5.34)

<1.0 × 10−6

rs10754558- rs1143623 (NLRP3-IL1B)

    

CC/CC

352 (0.141)

2,147 (0.179)

1.00

 

CC/CG

346 (0.139)

1,574 (0.131)

1.32 (1.09–1.60)

0.005

CC/GG

128 (0.051)

340 (0.028)

2.09 (1.57–2.78)

<1.0 × 10−6

CG/CC

497 (0.200)

2,963 (0.247)

1.00 (0.84–1.19)

1.00

CG/CG

529 (0.212)

2,312 (0.193)

1.30 (1.09–1.54)

0.004

CG/GG

184 (0.074)

524 (0.044)

1.43 (1.11–1.85)

0.005

GG/CC

209 (0.084)

1,099 (0.092)

1.22 (0.98–1.52)

0.072

GG/CG

179 (0.072)

851 (0.071)

1.14 (0.90–1.44)

0.272

GG/GG

66 (0.026)

173 (0.014)

1.70 (1.17–2.48)

0.006

a P Interaction was 0.91for CARD8/NLRP3, 0.005 for CARD8/IL1B, and 0.048 for NLRP3/IL1B. OR odds ratio

Discussion

TLR signalling via the NLRP3 inflammasome has been implicated in gout susceptibility and pathology in vivo and in vitro [10]; for example, MSU uptake and IL-1β production by bone marrow-derived macrophages derived from TLR2, TLR4 or Myd88 knockout mice is significantly reduced, as is neutrophil influx, in response to subcutaneous injection of MSU in whole animals [18]. To further elucidate the role of the TLR-inflammasome-IL-1β cascade in gout pathogenesis, eleven candidate genetic variants that functionally impact on this pathway (reviewed in [10]) were tested for association with gout in a sample set of 2,357 cases, adequately powered to detect association with common variants having an effect size of odds ratio 1.4 or greater (Additional file 1). As discussed below, the nominal evidence for association between gout and CD14, CARD8 and IL1B, and the multiplicative interaction between CARD8 and IL1B in determining the risk of gout, support the considerable evidence that TLR-mediated activation of the inflammasome and subsequent release of active IL-1β is a central causal pathogenic pathway of gout [10, 32].

Variants rs2043211 (CARD8), rs1143623 (IL1B) and rs2569190 (CD14), which were associated with gout, are functional variations in genes directly involved in the NLRP3 signaling pathway, and as such are likely to represent genuine disease-susceptibility loci. CARD8 is an adaptor protein that regulates IL-1β secretion by inhibiting NFKβ signaling (required for the expression of pro-IL-1β) and/or interacting with caspase 1 or NLRP3 to inhibit the generation of active IL-1β from inactive pro-IL-1β [13, 15]. The effect size of CARD8 SNP rs2043211 was consistent between the European and NZ Polynesian samples sets (OR = 1.11, P = 0.023 and OR = 1.15, P = 0.078, respectively; combined OR = 1.12, P = 0.007) and the Chinese sample set reported by Chen et al. (OR = 1.19, P = 0.08) [17]. Collectively our results and the study by Chen et al. [17] do suggest that the association of the minor allele of rs2043211 with gout is not a false positive one. SNP rs2043211 encodes a missense protein variation (C10X or F52I depending on transcript, [33]) with the minor allele increasing the risk of gout. Although the functional effect of this variation has not been specifically evaluated, the SNP is within an expression quantitative trait locus peak and carriage of the minor allele is associated with decreased CARD8 expression [34]. It has been inconsistently associated with other auto-inflammatory phenotypes, with some evidence for epistatic interaction with NLRP3 rs35829419 in determining risk of inflammatory bowel disease and abdominal aortic aneurysms [31, 35]. However, we found no evidence of interaction between NLRP3 and CARD8 in determining risk of gout (Table 4) (although we did not specifically analyse rs35829419), and it has also been suggested that under certain conditions, ASC-dependent IL1-β production in response to MSU stimulation can occur in the absence of NLRP3 [36].

IL1B SNP rs1143623 is within a promoter GATA transcription factor family binding site. Although the minor allele exhibits enhanced protein-binding [37] and decreased expression in vitro and in vivo, the effect of this variation seems to be influenced both by the wider promoter haplotype [38–40], and the identity of the stimulatory signal; the minor allele shows increased rather than decreased expression in vitro in response to TNF-α [40], and has also been associated with increased post-prandial triglyceride and IL6 (an effector of IL-1β) levels [41]. The minor allele is over-represented in gout cases compared to controls (OR = 1.10, P = 0.020). If this is replicated it would be consistent with an etiological role for increased IL1B expression in gout. There was evidence of multiplicative interaction with CARD8 rs2043211 in which the IL1B rs1143623 minor (risk) allele homozygous genotype appeared to amplify the effect of the minor allele of rs2043211. This would be consistent with a synergy of greater inflammasome activity (resulting from reduced CARD8) combined with higher levels of pre-IL-1β expression leading to increased production of mature IL-1β in gout.

The final variation nominally associated with gout was CD14 SNP rs2569190. This SNP is in the 5’UTR of one of the two CD14 splice variants, with the minor allele (that increases risk of gout) increasing expression in monocytes by decreasing affinity for the inhibitory Sp3 transcription factor [42], enhancing the loading of RNA polymerase II [43] and is associated with increased soluble CD14 levels in healthy individuals [44, 45]. Membrane-bound CD14 forms functional complexes with TLR2 or TLR4 and leukocyte β2-integrins, which could mediate TLR dimerization and optimize the innate immune response to MSU crystals [10].

Conclusions

In conclusion we provide evidence for association of gout with functional innate immune system variants in CARD8, IL1B and CD14, and multiplicative interaction between IL1B and CARD8. The findings involving IL1B are consistent with genetically determined levels of IL-1β being important in gout.

Footnotes
1

Note that the Meng et al paper [20] reported positive association with single nucleotide polymorphism (SNP) rs7512998, however the P value for this SNP had been incorrectly calculated - the true P value for rs7512998 was 0.43 - as reported in a corrigendum [61].

 

Abbreviations

ARA: 

American Rheumatology Association

ARIC: 

Atherosclerosis Risk in Communities

ASC: 

apoptosis-associated speck-like protein containing a CARDD

CARD8: 

caspase recruitment domain-containing protein 8

DAMP: 

damage-associated molecular pattern

EP: 

Eastern Polynesian

FHS: 

Framingham Heart Study

IL: 

interleukin

MAF: 

minor allele frequency

MSU: 

monosodium urate

NALP3: 

NACHT, LRR and PYD domains-containing protein 3

NLRP3: 

NOD-like Receptor Pyrin containing 3

NOD: 

nucleotide-binding oligomerisation domain

NZ: 

New Zealand

OR: 

odds ratio

PAMP: 

pathogen-associated molecular pattern

UTR: 

untranslated region

RNA: 

ribonucleic acid

SNP: 

single nucleotide polymorphism

TLR: 

toll-like receptor

TNF: 

tumour necrosis factor

WP: 

Western Polynesian

Declarations

Acknowledgements

This work was supported by the Health Research Council of New Zealand, Arthritis New Zealand, New Zealand Lottery Health and the University of Otago. The authors would like to thank Jill Drake (Canterbury District Health Board), Roddi Laurence, Chris Franklin, Meaghan House (all University of Auckland) and Gabrielle Sexton (University of Otago) for recruitment. Matthew Brown, Linda Bradbury and The Arthritis Genomics Recruitment Initiative in Australia network are acknowledged. The European Crystal Network was formed after the first European Crystal Workshop in Paris, March 2010 (Prof Frédéric Lioté, Paris, and Prof Alexander So, Lausanne, convenors). The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. The Framingham Heart Study and the Framingham SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University. The Framingham SHARe data used for the analyses described in this manuscript were obtained through dbGaP. This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University, or the NHLBI.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Biochemistry, University of Otago, Dunedin, New Zealand
(2)
Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand
(3)
Department of Medicine, University of Auckland, Auckland, New Zealand
(4)
School of Medical Sciences, University of New South Wales, Sydney, Australia
(5)
Department of Clinical Pharmacology & Toxicology, St Vincent’s Hospital, Sydney, Australia
(6)
Department of Rheumatology, Rijnstate Hospital, Arnhem, The Netherlands
(7)
Department of IQ HealthCare, VieCuri Medical Centre, Venlo, The Netherlands
(8)
Scientific Institute of Quality in HealthCare, Radboud University Medical Centre, Nijmegen, The Netherlands
(9)
Department of Internal Medicine and Radboud Institute of Molecular Life Science, Radboud University Medical Center, Nijmegen, The Netherlands
(10)
Department of Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
(11)
Department of Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
(12)
Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
(13)
Department of Rheumatology, University Clinic Carl-Gustav-Carus”, Dresden, Germany
(14)
INSERM, UMR-S 1132, Hospital Lariboisière, Paris, France
(15)
University Paris Diderot (UFR de Médecine), Sorbonne Paris Cité, Paris, France
(16)
DAL, Service of Rheumatology, Laboratory of Rheumatology, University of Lausanne, CHUV, Lausanne, Switzerland

References

  1. Dalbeth N, Haskard D. Mechanisms of inflammation in gout. Rheumatol. 2005;44:1090–6.View ArticleGoogle Scholar
  2. Emmerson BT, Nagel SL, Duffy DL, Martin NG. Genetic control of the renal clearance of urate: a study of twins. Ann Rheum Dis. 1992;51:375–7.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Gibson T, Waterworth R, Hatfield P, Robinson G, Bremner K. Hyperuricaemia, gout and kidney function in New Zealand Maori men. Br J Rheumatol. 1984;23:276–82.View ArticlePubMedGoogle Scholar
  4. Kottgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45:145–54.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Merriman TR, Choi HK, Dalbeth N. The genetic basis of gout. Rheum Dis Clin North Am. 2014;40:279–90.View ArticlePubMedGoogle Scholar
  6. Phipps-Green A, Merriman M, Topless R, Altaf S, Montgomery G, Franklin C, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2014-205877.
  7. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421–6.View ArticlePubMedGoogle Scholar
  8. Shi Y, Mucsi AD, Ng G. Monosodium urate crystals in inflammation and immunity. Immunological Rev. 2010;233:203–17.View ArticleGoogle Scholar
  9. Ryan JG, Goldbach-Mansky R. The spectrum of autoinflammatory diseases: recent bench to bedside observations. Curr Op Rheumatol. 2008;20:66–75.View ArticleGoogle Scholar
  10. Liu-Bryan R, Terkeltaub R. Tophus biology and pathogenesis of monosodium urate crystal–induced inflammation. Gout and Other Crystal Arthropathies. 2011;2011:59.Google Scholar
  11. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–61.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Ann Rev Immunol. 2009;27:229–65.View ArticleGoogle Scholar
  13. Razmara M, Srinivasula SM, Wang L, Poyet J-L, Geddes BJ, DiStefano PS, et al. CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis. J Biol Chem. 2002;277:13952–8.View ArticlePubMedGoogle Scholar
  14. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20:319–25.View ArticlePubMedGoogle Scholar
  15. Ito S, Hara Y, Kubota T. CARD8 is a negative regulator for NLRP3 inflammasome, but mutant NLRP3 in cryopyrin-associated periodic syndromes escapes the restriction. Arthritis Res Ther. 2014;16:R52.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Paramel G, Sirsjö A, Fransén K. Role of genetic alterations in the NLRP3 and CARD8 genes in health and disease. Mediators Inflamm. 2015;2015:846782.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Chen Y, Ren X, Li C, Xing S, Fu Z, Yuan Y, et al. CARD8 rs2043211 polymorphism is associated with gout in a Chinese male population. Cell Physiol Biochem. 2015;35:1394–400.View ArticlePubMedGoogle Scholar
  18. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2005;52:2936–46.View ArticlePubMedGoogle Scholar
  19. Qing Y-F, Zhou J-G, Zhang Q-B, Wang D-S, Li M, Yang Q-B, et al. Association of TLR4 gene rs2149356 polymorphism with primary gouty arthritis in a case-control study. PLoS One. 2013;8:64845.View ArticleGoogle Scholar
  20. Meng D-M, Zhou Y-J, Wang L, Ren W, Cui L-L, Han L, et al. Polymorphisms in the NLRP3 gene and risk of primary gouty arthritis. Mol Med Rep. 2013;7:1761–6.PubMedGoogle Scholar
  21. Winnard D, Wright C, Taylor WJ, Jackson G, Te Karu L, Gow PJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford). 2012;51:901–9.View ArticleGoogle Scholar
  22. Kuo C-F, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nature Rev Rheumatol. 2015. doi:10.1038/nrrhuem.2015.91.
  23. Liote F, Merriman T, Nasi S, So A. 4th European Crystal Netrowk meeting, Paris 8-9th March 2013. Arthritis Res Ther. 2013;15:304.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895–900.View ArticlePubMedGoogle Scholar
  25. Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, et al. The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol. 2012;74:477–89.PubMed CentralView ArticlePubMedGoogle Scholar
  26. www.ncbi.nim.nih/gov/dbgap. The database of Genotypes and Phenotypes.
  27. Hollis-Moffatt JE, Phipps-Green AJ, Chapman B, Jones GT, van Rij A, Gow PJ, et al. The renal urate transporter SLC17A1 locus: confirmation of association with gout. Arthritis Res Ther. 2012;14:R92.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190–1.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Cordell HJ. Detecting gene-gene interactions that underlie human diseases. Nature Rev Genet. 2009;10:392–404.PubMed CentralView ArticlePubMedGoogle Scholar
  30. Phipps-Green AJH-MJ, Dalbeth N, Merriman ME, Topless R, Gow PJ, Harrison AA, et al. A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Maori, case and control sample sets. Hum Mol Genet. 2010;19:4813–9.View ArticlePubMedGoogle Scholar
  31. Roberts R, Topless R, Phipps-Green A, Gearry R, Barclay M, Merriman T. Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes Immun. 2010;11:351–6.View ArticlePubMedGoogle Scholar
  32. Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther. 2010;12:206.PubMed CentralView ArticlePubMedGoogle Scholar
  33. http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2043211.
  34. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis. 2014;73:1202–10.View ArticlePubMedGoogle Scholar
  35. Roberts RL, Van Rij AM, Phillips LV, Young S, McCormick S, Merriman TR, et al. Interaction of the inflammasome genes CARD8 and NLRP3 in abdominal aortic aneurysms. Atherosclerosis. 2011;218:123–6.View ArticlePubMedGoogle Scholar
  36. Joosten LA, Netea MG, Mylona E, Koenders MI, Malireddi RK, Oosting M, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate crystal-induced gouty arthritis. Arthritis Rheum. 2010;62:3237–48.PubMed CentralView ArticlePubMedGoogle Scholar
  37. Lee K-A, Ki C-S, Kim H-J, Sohn K-M, Kim J-W, Kang WK, et al. Novel interleukin 1β polymorphism increased the risk of gastric cancer in a Korean population. J Gastoenterol. 2004;39:429–33.View ArticleGoogle Scholar
  38. Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, et al. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet. 2006;15:519–29.View ArticlePubMedGoogle Scholar
  39. Landvik NE, Hart K, Haugen A, Zienolddiny S. Functional analysis of a lung cancer risk haplotype in the IL1B gene regulatory region. J Hum Genet. 2012;57:747–52.View ArticlePubMedGoogle Scholar
  40. Landvik NE, Hart K, Skaug V, Stangeland LB, Haugen A, Zienolddiny S. A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. Carcinogenesis. 2009;30:1186–92.View ArticlePubMedGoogle Scholar
  41. Delgado-Lista J, Garcia-Rios A, Perez-Martinez P, Solivera J, Yubero-Serrano EM, Fuentes F, et al. Interleukin 1B variant-1473G/C (rs1143623) influences triglyceride and interleukin 6 metabolism. J Clin Endocrinol Metab. 2011;96:E816–20.PubMed CentralView ArticlePubMedGoogle Scholar
  42. LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol. 2001;167:5838–44.View ArticlePubMedGoogle Scholar
  43. Mertens J, Bregadze R, Mansur A, Askar E, Bickeböller H, Ramadori G, et al. Functional impact of endotoxin receptor CD14 polymorphisms on transcriptional activity. J Mol Med. 2009;87:815–24.PubMed CentralView ArticlePubMedGoogle Scholar
  44. LeVan TD, Michel O, Dentener M, Thorn J, Vertongen F, Beijer L, et al. Association between CD14 polymorphisms and serum soluble CD14 levels: Effect of atopy and endotoxin inhalation. J Allergy Clin Immunol. 2008;121:434–40.View ArticlePubMedGoogle Scholar
  45. Baldini M, Carla Lohman I, Halonen M, Erickson RP, Holt PG, Martinez FD. A Polymorphism in the 5’ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Resp Cell Mol Biol. 1999;20:976–83.View ArticleGoogle Scholar
  46. Hitomi Y, Ebisawa M, Tomikawa M, Imai T, Komata T, Hirota T, et al. Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. J Allergy Clin Immunol. 2009;124:779–85.View ArticlePubMedGoogle Scholar
  47. Verma D, Lerm M, Blomgran Julinder R, Eriksson P, Söderkvist P, Särndahl E. Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases? Arthritis Rheum. 2008;58:888–94.View ArticlePubMedGoogle Scholar
  48. Verma D, Särndahl E, Andersson H, Eriksson P, Fredrikson M, Jönsson J-I, et al. The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1β and IL-18 production. PLoS One. 2012;7:e34977.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Pontillo A, Vendramin A, Catamo E, Fabris A, Crovella S. The missense variation Q705K in CIAS1/NALP3/NLRP3 gene and an NLRP1 haplotype are associated with celiac disease. Am J Gastroenterol. 2011;106:539–44.View ArticlePubMedGoogle Scholar
  50. Fontalba AM-TV, Gutierrez O, Pipaon C, Benito N, Balsa A, Blanco R, et al. Deficiency of the NF-kappaB inhibitor caspase activating and recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity. J Immunol. 2007;179:4867–73.View ArticlePubMedGoogle Scholar
  51. Bagnall RD, Roberts RG, Mirza MM, Torigoe T, Prescott NJ, Mathew CG. Novel isoforms of the CARD8 (TUCAN) gene evade a nonsense mutation. Eur J Hum Genet. 2008;16:619–25.View ArticlePubMedGoogle Scholar
  52. Lacruz-Guzmán D, Torres-Moreno D, Pedrero F, Romero-Cara P, García-Tercero I, Trujillo-Santos J, et al. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis. Eur J Clin Pharmacol. 2013;69:431–8.View ArticlePubMedGoogle Scholar
  53. Harrison P, Pointon J, Chapman K, Roddam A, Wordsworth B. Interleukin-1 promoter region polymorphism role in rheumatoid arthritis: a meta-analysis of IL-1B-511A/G variant reveals association with rheumatoid arthritis. Rheumatol. 2008;47:1768–70.View ArticleGoogle Scholar
  54. Potaczek D, Nastalek M, Okumura K, Wojas‐Pelc A, Undas A, Nishiyama C. An association of TLR2–16934A > T polymorphism and severity/phenotype of atopic dermatitis. J Eur Acad Dermatol Venerol. 2011;25:715–21.View ArticleGoogle Scholar
  55. Wang Z, Hu J, Fan R, Zhou J, Zhong J. Association between CD14 gene C-260 T polymorphism and inflammatory bowel disease: a meta-analysis. PLoS One. 2012;7:e45144.PubMed CentralView ArticlePubMedGoogle Scholar
  56. Zhao L, Bracken MB. Association of CD14-260 (-159) C > T and asthma: a systematic review and meta-analysis. BMC Med genet. 2011;12:93.PubMed CentralView ArticlePubMedGoogle Scholar
  57. Wang Y, Sun C, Li T, Xu H, Zhou Y, Dan H, et al. Integrative approach detected association between genetic variants of microRNA binding sites of TLRs pathway genes and OSCC susceptibility in Chinese Han population. PLoS One. 2014;7:e101965.Google Scholar
  58. Roger S, Mei Z-Z, Baldwin JM, Dong L, Bradley H, Baldwin SA, et al. Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X 7 receptor functions. J Psychiatric Res. 2010;44:347–55.View ArticleGoogle Scholar
  59. Li Y, Grupe A, Rowland C, Nowotny P, Kauwe JS, Smemo S, et al. DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet. 2006;15:2560–8.View ArticlePubMedGoogle Scholar
  60. Ferreira NE, Omae S, Pereira A, Rodrigues MV, Miyakawa AA, Campos LC, et al. Thioredoxin interacting protein genetic variation is associated with diabetes and hypertension in the Brazilian general population. Atherosclerosis. 2012;221:131–6.View ArticlePubMedGoogle Scholar
  61. Meng D-M, Zhou Y-J, Wang L, Ren W, Cui L-L, Han L, et al. Erratum: Polymorphisms in the NLRP3 gene and risk of primary gouty arthritis. Mol Med Rep. 2013;8:1888.Google Scholar

Copyright

© McKinney et al. 2015

Advertisement

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us